Pharmaceuticals & Biotechnology | Pharma & Biotech Resources
Summary: Pharma IQ, a division of IQPC, is an international online community focusing on providing pharmaceutical professionals with knowledge, information and articles. We are dedicated to creating a learning environment for sharing ideas, best practices and solutions within the pharmaceutical community Through Pharma IQ, you will be able to access pharmaceutical information resources such as
- Visit Website
- RSS
- Artist: Unknown
Podcasts:
Pharma IQ interviewed Adrian Peskett, Clinical Supply Logistics Director at Pfizer Ltd. about his predictions for the future of clinical trial supply in emerging markets. Adrian also speaks about the importance of forecasting in emerging markets and the difficulties in standardising
Many companies struggle to understand regulatory expectations of their submissions which can lead to long and costly delays. We spoke to Arnab Ray, Senior Research Scientist at the Franuhofer Center who gave us his key points to ensuring a smooth regulatory submission process
Why are NASA using human stem cells to study the chicken pox virus? How could this help astronauts in space? How is the Mars Rover mission helping? And why are the Russians so interested? Find out with Thomas J. Goodwin, Manager, Disease Modelling/Tissue Analogues
With increasing software sophistication and complexity, are security vulnerabilities an inevitability? We spoke with Arnab Ray, Senior Research Scientist at the Franuhofer Center about the issues surrounding device security and how the will effect companies in the coming years.
Should companies be communicating more clearly with their site teams with regard to their expectations? We spoke to Samantha Carmichael, Lead Pharmacist Clinical Trials at NHS Greater Glasgow & Clyde to gain insight into challenges for sites from the different stages in clinical
Artemisinin is a front line anti-malarial drug which was derived from the sweet wormwood plant. ‘Growing on trees’ however, isn’t all it’s cracked up to be and the supply could be unpredictable. Professor Jay Keasling, using synthetic biology techniques, had
With over 30 years in the industry, Chuck Sidebottom Director of Corporate Standards at Medtronic is excellently placed to analyse trends in the medical device industry. When he spoke with Pharma IQ, Chuck discussed recent shifts in regulatory emphasis and predicted how
Ahead of the Cell Based Assays Conference in December, Pharma IQ spoke with Jorrit Hornberg about the advances in vitro and in silico predictive toxicology and what this means for in vivo assays. He also spoke about the challenges in incorporating predictive toxicology into drug
Ahead of the Cell Based Assays Conference in December, Pharma IQ spoke with Jorrit Hornberg about the advances in vitro and in silico predictive toxicology and what this means for in vivo assays. He also spoke about the challenges in incorporating predictive toxicology into drug
How do you find out the industry opinion on a topic? Simply, speak with them. Senior Conference Producer John Shah has spoken with hundreds of professionals working in pathogen safety from industry and regulatory perspectives. Our Editor Gerald Clarke spoke to him about what he has
How do you find out the industry opinion on a topic? Simply, speak with them. Senior Conference Producer John Shah has spoken with hundreds of professionals working in pathogen safety from industry and regulatory perspectives. Our Editor Gerald Clarke spoke to him about what he has
Benedikt B. Kaufer Project Director, Institute for Virologyat the Freie Universität Berlin speaks about his remarkable NASA-funded study published in Plos Pathology. The paper regarded using Tissue Like Arrays (TLAs) for modelling disease in human neurons. Varicella
In 2008 and 2009, Genzyme sites were affected by vesivirus infection. This shut down two sites for decontamination. In this candid interview, Lada Laenen, Managing Principal Scientist, Head, Cell Culture and Microbiology, Genzyme, a Sanofi Company, discusses how this
As part of our Future Pharma Series, we spoke to Dr. Stephen Minger, Chief Scientist, Research and Applied Markets at Life Sciences, GE Healthcare about the future of regenerative medicine. As he sits on the board of directors for the Centre for Commercialization of Regenerative
As part of our Future Pharma Series, we spoke to Dr. Stephen Minger, Chief Scientist, Research and Applied Markets at Life Sciences, GE Healthcare about the future of regenerative medicine. As he sits on the board of directors for the Centre for Commercialization of Regenerative
